Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Center for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Department of Pathology, University of Colorado, Aurora, CO 80045, USA.
Am J Hum Genet. 2020 Jul 2;107(1):72-82. doi: 10.1016/j.ajhg.2020.05.005. Epub 2020 Jun 6.
Genetics researchers and clinical professionals rely on diversity measures such as race, ethnicity, and ancestry (REA) to stratify study participants and patients for a variety of applications in research and precision medicine. However, there are no comprehensive, widely accepted standards or guidelines for collecting and using such data in clinical genetics practice. Two NIH-funded research consortia, the Clinical Genome Resource (ClinGen) and Clinical Sequencing Evidence-generating Research (CSER), have partnered to address this issue and report how REA are currently collected, conceptualized, and used. Surveying clinical genetics professionals and researchers (n = 448), we found heterogeneity in the way REA are perceived, defined, and measured, with variation in the perceived importance of REA in both clinical and research settings. The majority of respondents (>55%) felt that REA are at least somewhat important for clinical variant interpretation, ordering genetic tests, and communicating results to patients. However, there was no consensus on the relevance of REA, including how each of these measures should be used in different scenarios and what information they can convey in the context of human genetics. A lack of common definitions and applications of REA across the precision medicine pipeline may contribute to inconsistencies in data collection, missing or inaccurate classifications, and misleading or inconclusive results. Thus, our findings support the need for standardization and harmonization of REA data collection and use in clinical genetics and precision health research.
遗传学家和临床专业人员依靠种族、民族和血统(REA)等多样性措施来对研究参与者和患者进行分层,以应用于研究和精准医学的各种领域。然而,在临床遗传学实践中,并没有用于收集和使用此类数据的全面、广泛认可的标准或准则。两个由 NIH 资助的研究联盟,临床基因组资源(ClinGen)和临床测序证据生成研究(CSER),已经合作来解决这个问题,并报告了 REA 目前是如何被收集、概念化和使用的。对临床遗传学专业人员和研究人员(n = 448)进行调查后,我们发现,REA 在被感知、定义和衡量的方式上存在异质性,并且在临床和研究环境中,REA 的重要性也存在差异。大多数受访者(>55%)认为,REA 对于临床变异解释、遗传检测的选择和向患者传达结果至少在一定程度上是重要的。然而,对于 REA 的相关性,包括如何在不同情况下使用这些措施以及它们在人类遗传学背景下可以传达哪些信息,并没有达成共识。在精准医学领域,REA 的定义和应用缺乏通用性,这可能导致数据收集不一致、分类缺失或不准确,以及结果误导或不明确。因此,我们的研究结果支持在临床遗传学和精准健康研究中标准化和协调 REA 数据收集和使用的必要性。